Legend Biotech Key Executives
This section highlights Legend Biotech's key executives, including their titles and compensation details.
Find Contacts at Legend Biotech
(Showing 0 of )
Legend Biotech Earnings
This section highlights Legend Biotech's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-11 | $-0.39 | $-0.15 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $-0.56 | $-0.34 |
| Read Transcript | Q1 | 2024 | 2024-05-13 | $-0.29 | $-0.16 |
| Read Transcript | Q4 | 2023 | 2024-03-11 | $-0.70 | $-0.40 |
| Read Transcript | Q3 | 2023 | 2023-11-20 | $-0.56 | $-0.17 |
| Read Transcript | Q2 | 2023 | 2023-08-15 | $-0.69 | $-0.27 |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
$32.00
Stock Price
$2.94B
Market Cap
2.60K
Employees
Somerset, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Legend Biotech, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $627.24M | $285.14M | $117.00M | $89.79M | $75.68M |
| Cost of Revenue | $234.58M | $144.21M | $65.36M | $313.35M | $232.16M |
| Gross Profit | $392.66M | $140.93M | $51.64M | $-223.55M | $-156.48M |
| Gross Profit Ratio | 62.60% | 49.42% | 44.14% | -248.97% | -206.78% |
| Research and Development Expenses | $413.54M | $382.22M | $335.65M | $313.35M | $232.16M |
| General and Administrative Expenses | $136.78M | $106.77M | $80.63M | $46.94M | $23.15M |
| Selling and Marketing Expenses | $147.48M | $94.16M | $93.42M | $102.54M | $49.57M |
| Selling General and Administrative Expenses | $284.26M | $200.93M | $174.05M | $149.48M | $72.72M |
| Other Expenses | $-1.91M | $- | $2.23M | $-6.07M | $-74.21M |
| Operating Expenses | $695.90M | $140.93M | $509.70M | $462.83M | $304.88M |
| Cost and Expenses | $930.48M | $727.36M | $575.06M | $462.83M | $304.88M |
| Interest Income | $61.20M | $54.49M | $8.18M | $971.00K | $2.93M |
| Interest Expense | $21.61M | $21.79M | $10.80M | $900.00K | $4.21M |
| Depreciation and Amortization | $23.36M | $20.45M | $18.39M | $13.92M | $9.93M |
| EBITDA | $-113.16M | $-477.87M | $-416.54M | $-392.38M | $-294.14M |
| EBITDA Ratio | -18.04% | -167.59% | -356.00% | -436.99% | -388.69% |
| Operating Income | $-303.24M | $-439.49M | $-455.83M | $-393.02M | $-313.35M |
| Operating Income Ratio | -48.35% | -154.13% | -389.58% | -437.71% | -414.06% |
| Total Other Income Expenses Net | $145.11M | $-80.63M | $10.10M | $-14.17M | $-78.41M |
| Income Before Tax | $-158.13M | $-520.12M | $-445.72M | $-386.21M | $-307.62M |
| Income Before Tax Ratio | -25.21% | -182.41% | -380.94% | -430.11% | -406.50% |
| Income Tax Expense | $18.89M | $-1.86M | $625.00K | $1.00K | $-4.14M |
| Net Income | $-177.03M | $-518.25M | $-446.35M | $-386.21M | $-303.48M |
| Net Income Ratio | -28.22% | -181.75% | -381.48% | -430.12% | -401.02% |
| EPS | $-0.97 | $-2.94 | $-2.81 | $-2.74 | $-2.57 |
| EPS Diluted | $-0.97 | $-2.94 | $-2.81 | $-2.74 | $-2.57 |
| Weighted Average Shares Outstanding | 182.85M | 176.08M | 159.04M | 140.85M | 118.15M |
| Weighted Average Shares Outstanding Diluted | 182.85M | 176.08M | 159.04M | 140.85M | 118.15M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $186.52M | $160.21M | $186.52M | $93.99M | $79.46M | $96.01M | $73.33M | $36.34M | $27.63M | $27.36M | $11.97M | $40.83M | $38.99M | $16.88M | $20.23M | $13.68M | $40.78M | $11.75M | $11.60M | $11.55M |
| Cost of Revenue | $73.92M | $55.47M | $50.45M | $60.46M | $37.80M | $43.48M | $32.67M | $35.61M | $22.96M | $25.46M | $16.94M | $81.35M | $- | $- | $- | $71.07M | $- | $- | $- | $- |
| Gross Profit | $112.60M | $104.74M | $136.07M | $33.53M | $41.66M | $52.53M | $40.66M | $723.00K | $4.67M | $1.90M | $-4.97M | $-40.52M | $38.99M | $16.88M | $20.23M | $-57.39M | $40.78M | $11.75M | $11.60M | $11.55M |
| Gross Profit Ratio | 60.37% | 65.38% | 72.95% | 35.67% | 52.43% | 54.72% | 55.45% | 1.99% | 16.90% | 6.95% | -41.50% | -99.25% | 100.00% | 100.00% | 100.00% | -419.46% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $104.43M | $95.52M | $112.63M | $100.96M | $105.68M | $95.86M | $95.79M | $84.89M | $80.76M | $104.52M | $68.83M | $81.35M | $86.50M | $72.31M | $83.46M | $71.07M | $66.93M | $63.66M | $53.57M | $48.00M |
| General and Administrative Expenses | $34.20M | $35.30M | $35.35M | $31.93M | $28.71M | $28.10M | $27.75M | $22.20M | $26.68M | $23.24M | $18.05M | $12.66M | $17.14M | $11.81M | $9.25M | $8.74M | $9.17M | $6.04M | $4.51M | $3.43M |
| Selling and Marketing Expenses | $48.92M | $44.27M | $30.06M | $24.22M | $33.68M | $21.10M | $21.43M | $17.95M | $25.82M | $18.85M | $27.44M | $21.30M | $52.81M | $19.53M | $16.78M | $13.42M | $24.18M | $9.29M | $9.56M | $6.54M |
| Selling General and Administrative Expenses | $83.13M | $79.57M | $65.42M | $50.43M | $57.03M | $49.20M | $49.18M | $40.16M | $52.50M | $42.09M | $45.49M | $33.96M | $69.95M | $31.34M | $26.03M | $22.16M | $33.35M | $15.32M | $14.06M | $9.97M |
| Other Expenses | $-563.00K | $-70.36M | $- | $-440.00K | $-28.18M | $6.94M | $-4.46M | $-2.54M | $169.00K | $-2.40M | $-6.24M | $-502.00K | $-1.47M | $-3.13M | $-2.23M | $-1.31M | $1.79M | $270.00K | $-78.76M | $-45.00K |
| Operating Expenses | $187.00M | $104.74M | $178.04M | $151.39M | $162.72M | $144.88M | $143.62M | $125.05M | $131.89M | $145.55M | $114.32M | $114.80M | $156.46M | $103.50M | $108.17M | $93.23M | $100.29M | $78.98M | $67.63M | $56.87M |
| Cost and Expenses | $260.92M | $160.21M | $228.49M | $211.85M | $200.52M | $188.36M | $176.29M | $160.66M | $154.86M | $171.01M | $131.26M | $114.80M | $156.46M | $103.50M | $108.17M | $93.23M | $100.29M | $78.98M | $67.63M | $56.87M |
| Interest Income | $13.65M | $16.63M | $17.05M | $13.87M | $17.30M | $18.42M | $5.18M | $5.11M | $4.89M | $36.50K | $- | $458.00K | $423.00K | $321.00K | $- | $100.00K | $- | $- | $- | $849.00K |
| Interest Expense | $5.15M | $5.50M | $5.48M | $5.47M | $5.82M | $5.68M | $5.18M | $5.11M | $4.86M | $3.25M | $1.64M | $994.00K | $602.00K | $208.00K | $52.00K | $38.00K | $40.00K | $90.00K | $88.00K | $3.99M |
| Depreciation and Amortization | $6.80M | $5.47M | $5.37M | $5.72M | $5.35M | $5.17M | $2.65M | $5.18M | $5.25M | $5.11M | $4.11M | $3.93M | $3.71M | $3.50M | $3.35M | $3.68M | $1.36M | $2.47M | $2.80M | $2.02M |
| EBITDA | $52.46M | $-109.91M | $-7.12M | $-48.59M | $-135.64M | $-51.65M | $-193.65M | $-106.86M | $-125.61M | $-81.56M | $-191.43M | $-31.08M | $-87.73M | $-121.69M | $-88.18M | $-80.86M | $-57.72M | $-66.96M | $-134.79M | $-41.92M |
| EBITDA Ratio | 28.12% | -68.61% | -3.82% | -51.70% | -170.69% | -53.79% | -264.08% | -294.09% | -454.58% | -298.07% | -1599.10% | -76.13% | -224.98% | -720.80% | -435.81% | -591.00% | -141.52% | -570.05% | -1161.97% | -363.11% |
| Operating Income | $-74.39M | $- | $-41.55M | $-117.86M | $-121.05M | $-66.99M | $-88.66M | $-106.86M | $319.25M | $-142.76M | $-119.28M | $-74.99M | $-91.44M | $-128.04M | $-89.25M | $-79.55M | $-56.43M | $-67.23M | $-56.03M | $-43.95M |
| Operating Income Ratio | -39.89% | 0.00% | -22.28% | -125.40% | -152.34% | -69.77% | -120.90% | -294.09% | 1155.33% | -521.75% | -996.45% | -183.68% | -234.50% | -758.45% | -441.14% | -581.41% | -138.37% | -572.35% | -483.03% | -380.62% |
| Total Other Income Expenses Net | $114.91M | $-120.89M | $23.58M | $58.08M | $-25.76M | $30.03M | $-110.18M | $11.64M | $-8.50M | $58.84M | $-73.79M | $33.34M | $28.83M | $-38.78M | $-2.33M | $12.35M | $1.33M | $180.00K | $-78.84M | $-1.50M |
| Income Before Tax | $40.51M | $-120.89M | $-17.97M | $-59.79M | $-146.81M | $-62.49M | $-198.84M | $-111.97M | $-135.72M | $-84.80M | $-193.07M | $-41.09M | $-88.33M | $-125.39M | $-91.58M | $-80.90M | $-57.76M | $-67.05M | $-134.88M | $-47.94M |
| Income Before Tax Ratio | 21.72% | -75.46% | -9.63% | -63.61% | -184.75% | -65.09% | -271.16% | -308.16% | -491.16% | -309.94% | -1612.82% | -100.64% | -226.53% | -742.76% | -452.64% | -591.28% | -141.62% | -570.82% | -1162.72% | -415.18% |
| Income Tax Expense | $14.23M | $4.43M | $226.00K | $5.00K | $-1.99M | $-288.00K | $290.00K | $128.00K | $153.00K | $152.00K | $157.00K | $994.00K | $-3.71M | $-3.50M | $1.00K | $1.31M | $72.00K | $-508.00K | $78.76M | $-3.71M |
| Net Income | $26.28M | $-125.32M | $-18.20M | $-59.79M | $-144.82M | $-62.21M | $-199.13M | $-112.10M | $-135.88M | $-84.96M | $-193.23M | $-42.08M | $-88.33M | $-125.39M | $-91.58M | $-80.90M | $-57.83M | $-66.55M | $-134.88M | $-44.23M |
| Net Income Ratio | 14.09% | -78.23% | -9.76% | -63.62% | -182.24% | -64.79% | -271.55% | -308.51% | -491.72% | -310.50% | -1614.13% | -103.07% | -226.53% | -742.76% | -452.65% | -591.28% | -141.79% | -566.49% | -1162.72% | -383.06% |
| EPS | $0.14 | $0.00 | $-0.10 | $-0.33 | $-0.80 | $-0.34 | $-1.14 | $-0.68 | $-0.85 | $-0.27 | $-1.25 | $-0.27 | $-0.60 | $-0.87 | $-0.66 | $-0.61 | $-0.44 | $-0.50 | $-1.25 | $-0.34 |
| EPS Diluted | $0.14 | $0.00 | $-0.10 | $-0.33 | $-0.80 | $-0.34 | $-1.14 | $-0.68 | $-0.85 | $-0.27 | $-1.25 | $-0.27 | $-0.60 | $-0.87 | $-0.66 | $-0.61 | $-0.44 | $-0.50 | $-1.25 | $-0.34 |
| Weighted Average Shares Outstanding | 182.85M | - | 182.60M | 182.01M | 181.91M | 181.79M | 175.26M | 165.25M | 159.04M | 314.09M | 154.89M | 154.35M | 146.60M | 144.96M | 138.51M | 133.15M | 132.36M | 132.16M | 107.59M | 129.35M |
| Weighted Average Shares Outstanding Diluted | 182.85M | - | 182.60M | 182.01M | 181.91M | 181.79M | 175.26M | 165.25M | 159.04M | 314.09M | 154.89M | 154.35M | 146.60M | 144.96M | 138.51M | 133.15M | 132.36M | 132.16M | 107.78M | 129.35M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $286.75M | $1.28B | $786.03M | $688.94M | $455.69M |
| Short Term Investments | $835.93M | $31.00M | $239.62M | $193.46M | $50.00M |
| Cash and Short Term Investments | $1.12B | $1.31B | $1.03B | $882.39M | $505.69M |
| Net Receivables | $124.89M | $157.06M | $45.52M | $50.50M | $75.62M |
| Inventory | $23.90M | $19.43M | $10.35M | $1.75M | $1.80M |
| Other Current Assets | $12.44M | $12.59M | $62.84M | $15.20M | $10.84M |
| Total Current Assets | $1.28B | $1.50B | $1.10B | $948.75M | $592.86M |
| Property Plant Equipment Net | $201.59M | $189.68M | $161.67M | $155.08M | $121.32M |
| Goodwill | $- | $- | $- | $- | $-4.85M |
| Intangible Assets | $174.22M | $4.06M | $3.41M | $4.68M | $7.70M |
| Goodwill and Intangible Assets | $174.22M | $4.06M | $3.41M | $4.68M | $2.85M |
| Long Term Investments | $4.36M | $4.36M | $395.00K | $4.71M | $- |
| Tax Assets | $- | $285.00K | $-395.00K | $- | $- |
| Other Non-Current Assets | $6.06M | $152.42M | $66.76M | $5.15M | $3.97M |
| Total Non-Current Assets | $386.24M | $350.81M | $231.84M | $169.62M | $128.15M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.67B | $1.85B | $1.33B | $1.12B | $721.01M |
| Account Payables | $37.19M | $20.16M | $32.89M | $7.04M | $4.91M |
| Short Term Debt | $4.79M | $3.17M | $7.13M | $911.00K | $1.46M |
| Tax Payables | $24.04M | $7.20M | $9.77M | $515.00K | $8.79M |
| Deferred Revenue | $47.41M | $53.01M | $451.00K | $60.95M | $55.30M |
| Other Current Liabilities | $164.21M | $132.87M | $248.00M | $220.74M | $100.11M |
| Total Current Liabilities | $277.64M | $216.42M | $297.79M | $280.27M | $161.17M |
| Long Term Debt | $345.81M | $325.50M | $280.97M | $122.06M | $1.91M |
| Deferred Revenue Non-Current | $6.15M | $55.27M | $7.66M | $242.58M | $275.07M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $1.87M | $2.05M |
| Other Non-Current Liabilities | $- | $56.00K | $7.89M | $2.26M | $2.60M |
| Total Non-Current Liabilities | $351.96M | $380.82M | $288.86M | $366.89M | $279.58M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $629.61M | $597.24M | $586.65M | $647.16M | $440.75M |
| Preferred Stock | $- | $- | $222.14M | $- | $- |
| Common Stock | $37.00K | $36.00K | $33.00K | $31.00K | $27.00K |
| Retained Earnings | $-1.66B | $-1.48B | $-966.46M | $-816.97M | $-430.76M |
| Accumulated Other Comprehensive Income Loss | $-68.16M | $98.92M | $744.28M | $471.18M | $280.23M |
| Other Total Stockholders Equity | $2.77B | $2.64B | $1.66B | $1.26B | $708.31M |
| Total Stockholders Equity | $1.04B | $1.25B | $744.31M | $471.21M | $280.25M |
| Total Equity | $1.04B | $1.25B | $744.31M | $471.21M | $280.25M |
| Total Liabilities and Stockholders Equity | $1.67B | $1.85B | $1.33B | $1.12B | $721.01M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.67B | $1.85B | $1.33B | $1.12B | $721.01M |
| Total Investments | $840.30M | $35.37M | $239.62M | $198.16M | $50.00M |
| Total Debt | $350.60M | $328.67M | $284.53M | $122.97M | $3.37M |
| Net Debt | $63.85M | $-949.04M | $-501.50M | $-565.97M | $-452.32M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $286.75M | $459.28M | $201.68M | $897.93M | $1.28B | $963.47M | $1.23B | $660.05M | $786.03M | $786.03M | $379.78M | $377.79M | $688.94M | $338.33M | $488.21M | $412.30M | $455.69M | $449.38M | $562.39M | $168.80M |
| Short Term Investments | $835.93M | $753.12M | $1.09B | $404.81M | $31.00M | $460.37M | $281.57M | $190.07M | $239.62M | $54.02M | $403.33M | $413.47M | $193.46M | $297.60M | $204.49M | $50.00M | $50.00M | $126.73M | $75.56M | $77.68M |
| Cash and Short Term Investments | $1.12B | $1.21B | $1.29B | $1.30B | $1.31B | $1.42B | $1.51B | $850.12M | $1.03B | $1.03B | $783.11M | $791.26M | $882.39M | $635.93M | $692.71M | $462.30M | $505.69M | $576.12M | $637.95M | $246.48M |
| Net Receivables | $124.89M | $103.98M | $101.38M | $77.96M | $157.06M | $49.69M | $62.90M | $56.00K | $278.00K | $278.00K | $461.00K | $50.45M | $50.41M | $1.50M | $15.00M | $- | $74.98M | $- | $- | $- |
| Inventory | $23.90M | $23.55M | $18.87M | $22.15M | $19.43M | $18.01M | $15.20M | $12.18M | $10.35M | $10.35M | $8.16M | $2.90M | $1.75M | $1.63M | $1.70M | $2.10M | $1.80M | $1.51M | $1.67M | $1.33M |
| Other Current Assets | $12.44M | $10.11M | $12.75M | $11.31M | $12.59M | $17.26M | $19.99M | $53.04M | $62.84M | $62.84M | $44.22M | $18.10M | $14.20M | $14.29M | $11.43M | $10.68M | $10.39M | $25.09M | $33.77M | $21.87M |
| Total Current Assets | $1.28B | $1.35B | $1.42B | $1.41B | $1.50B | $1.51B | $1.61B | $915.40M | $1.10B | $1.10B | $835.95M | $862.71M | $948.75M | $653.36M | $720.83M | $475.07M | $592.86M | $602.72M | $673.39M | $271.22M |
| Property Plant Equipment Net | $201.59M | $203.86M | $220.03M | $186.02M | $189.68M | $184.73M | $190.54M | $192.70M | $161.67M | $160.76M | $145.79M | $163.66M | $155.08M | $150.40M | $144.72M | $132.12M | $121.32M | $104.88M | $98.50M | $93.22M |
| Goodwill | $- | $- | $- | $- | $- | $- | $-119.17M | $-93.55M | $- | $- | $- | $106.00K | $- | $- | $- | $- | $-4.85M | $- | $- | $- |
| Intangible Assets | $174.22M | $175.49M | $2.77M | $169.50M | $155.28M | $140.01M | $121.64M | $95.84M | $68.69M | $3.41M | $4.62M | $4.41M | $4.68M | $5.43M | $4.68M | $4.08M | $7.70M | $1.04M | $978.00K | $491.00K |
| Goodwill and Intangible Assets | $174.22M | $175.49M | $2.77M | $169.50M | $155.28M | $140.01M | $2.46M | $2.29M | $68.69M | $3.41M | $4.62M | $4.52M | $4.68M | $5.43M | $4.68M | $4.08M | $2.85M | $1.04M | $978.00K | $491.00K |
| Long Term Investments | $4.36M | $4.51M | $4.40M | $4.39M | $4.65M | $4.27M | $4.21M | $4.37M | $395.00K | $- | $4.47M | $4.73M | $4.71M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $1 | $-166.34M | $-151.22M | $- | $119.17M | $- | $-395.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.06M | $1.93M | $146.15M | $167.76M | $152.42M | $1.53M | $1.41M | $94.61M | $1.49M | $-164.17M | $31.91M | $4.91M | $5.15M | $4.57M | $4.88M | $3.98M | $3.97M | $- | $- | $- |
| Total Non-Current Assets | $386.24M | $385.79M | $373.35M | $361.31M | $350.81M | $330.54M | $317.80M | $293.96M | $231.84M | $164.17M | $186.80M | $177.81M | $169.62M | $160.40M | $154.29M | $140.18M | $128.15M | $105.92M | $99.47M | $93.71M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $67.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.67B | $1.74B | $1.80B | $1.78B | $1.85B | $1.84B | $1.93B | $1.21B | $1.33B | $1.33B | $1.02B | $1.04B | $1.12B | $813.76M | $875.12M | $615.25M | $721.01M | $708.64M | $772.87M | $364.94M |
| Account Payables | $37.19M | $26.91M | $39.49M | $39.48M | $20.16M | $17.17M | $21.54M | $29.81M | $32.89M | $32.89M | $12.24M | $9.71M | $7.04M | $11.59M | $11.00M | $9.65M | $4.91M | $7.40M | $6.98M | $10.12M |
| Short Term Debt | $4.79M | $4.34M | $3.33M | $3.12M | $3.17M | $2.92M | $3.56M | $4.59M | $3.56M | $- | $2.12M | $883.00K | $911.00K | $1.12M | $1.18M | $1.46M | $1.46M | $1.45M | $1.31M | $1.42M |
| Tax Payables | $24.04M | $13.03M | $6.57M | $7.27M | $7.20M | $11.62M | $13.56M | $9.94M | $10.79M | $- | $9.34M | $9.56M | $515.00K | $- | $- | $- | $8.95M | $- | $- | $- |
| Deferred Revenue | $47.41M | $63.72M | $75.39M | $63.25M | $53.01M | $630.00K | $435.00K | $457.00K | $451.00K | $- | $315.00K | $65.88M | $60.95M | $56.12M | $56.44M | $54.74M | $55.30M | $46.79M | $46.31M | $46.09M |
| Other Current Liabilities | $164.21M | $162.90M | $169.53M | $136.01M | $132.80M | $143.51M | $162.72M | $193.84M | $250.54M | $264.89M | $235.74M | $205.37M | $271.80M | $206.84M | $192.78M | $80.38M | $145.84M | $67.89M | $60.43M | $54.79M |
| Total Current Liabilities | $277.64M | $270.89M | $294.30M | $249.68M | $216.42M | $175.22M | $201.38M | $238.18M | $297.79M | $297.79M | $259.76M | $225.53M | $280.27M | $275.37M | $261.10M | $145.94M | $161.17M | $123.52M | $115.03M | $112.43M |
| Long Term Debt | $345.81M | $342.25M | $335.60M | $331.57M | $325.50M | $317.59M | $315.06M | $310.17M | $280.97M | $260.93M | $193.60M | $128.34M | $122.06M | $72.41M | $18.93M | $1.67M | $1.91M | $2.54M | $2.12M | $3.34M |
| Deferred Revenue Non-Current | $6.15M | $6.55M | $9.28M | $23.11M | $47.96M | $6.76M | $7.04M | $7.63M | $- | $- | $6.45M | $247.72M | $242.58M | $239.13M | $254.62M | $260.63M | $275.07M | $247.67M | $254.71M | $265.05M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $45.17M | $44.17M | $-6.76M | $-7.04M | $-7.63M | $- | $- | $- | $- | $1.87M | $- | $- | $- | $2.05M | $-194.58M | $-202.23M | $-210.75M |
| Other Non-Current Liabilities | $- | $27.00K | $- | $23.14M | $48.02M | $6.88M | $7.19M | $7.86M | $7.89M | $-260.93M | $314.00K | $356.00K | $244.84M | $991.00K | $554.00K | $261.19M | $273.44M | $- | $- | $- |
| Total Non-Current Liabilities | $351.96M | $348.82M | $344.88M | $354.71M | $373.51M | $324.48M | $322.25M | $318.02M | $288.86M | $260.93M | $200.36M | $376.42M | $366.89M | $312.53M | $274.11M | $262.86M | $279.58M | $250.22M | $256.83M | $268.38M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $27.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $629.61M | $619.72M | $639.18M | $604.38M | $589.93M | $499.70M | $523.63M | $556.20M | $586.65M | $586.65M | $460.11M | $601.95M | $647.16M | $587.90M | $535.21M | $408.80M | $440.75M | $373.74M | $371.86M | $380.82M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $1.28B | $- | $951.75M | $- | $- | $- | $- | $- | $- | $- | $116.50M | $- | $- | $167.60M |
| Common Stock | $37.00K | $37.00K | $37.00K | $36.00K | $36.00K | $36.00K | $36.00K | $33.00K | $33.00K | $33.00K | $31.00K | $31.00K | $31.00K | $29.00K | $29.00K | $27.00K | $27.00K | $26.00K | $26.00K | $22.00K |
| Retained Earnings | $-1.66B | $-1.69B | $-1.56B | $-1.54B | $-1.48B | $-1.34B | $-1.28B | $- | $-966.46M | $-966.46M | $- | $- | $-520.11M | $-728.63M | $-603.24M | $- | $-116.53M | $- | $- | $-171.51M |
| Accumulated Other Comprehensive Income Loss | $-68.16M | $47.68M | $46.45M | $62.66M | $98.92M | $966.00K | $1.41B | $653.12M | $14.67M | $- | $562.60M | $438.53M | $471.18M | $225.84M | $339.89M | $206.42M | $280.23M | $334.87M | $400.98M | $-15.90M |
| Other Total Stockholders Equity | $2.77B | $2.76B | $2.68B | $2.65B | $2.64B | $2.63B | $- | $- | $1.66B | $1.71B | $- | $- | $991.28M | $935.98M | $- | $- | $708.31M | $- | $- | $-13.25M |
| Total Stockholders Equity | $1.04B | $1.12B | $1.16B | $1.16B | $1.25B | $1.34B | $1.41B | $653.16M | $744.31M | $744.31M | $562.63M | $438.56M | $471.21M | $225.87M | $339.92M | $206.45M | $280.25M | $334.90M | $401.00M | $-15.88M |
| Total Equity | $1.04B | $1.12B | $1.16B | $1.16B | $1.25B | $1.34B | $1.41B | $653.16M | $744.31M | $744.31M | $562.63M | $438.56M | $471.21M | $225.87M | $339.92M | $206.45M | $280.25M | $334.90M | $401.00M | $-15.88M |
| Total Liabilities and Stockholders Equity | $1.67B | $1.74B | $1.80B | $1.78B | $1.85B | $1.84B | $1.93B | $1.21B | $1.33B | $- | $1.02B | $1.04B | $1.12B | $813.76M | $875.12M | $615.25M | $721.01M | $708.64M | $772.87M | $364.94M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.67B | $1.74B | $1.80B | $1.78B | $1.85B | $1.84B | $1.93B | $1.21B | $1.33B | $- | $1.02B | $1.04B | $1.12B | $813.76M | $875.12M | $615.25M | $721.01M | $708.64M | $772.87M | $364.94M |
| Total Investments | $840.30M | $757.63M | $1.09B | $409.19M | $35.65M | $464.63M | $285.78M | $194.44M | $239.62M | $54.02M | $407.80M | $418.20M | $198.16M | $297.60M | $204.49M | $50.00M | $50.00M | $126.73M | $75.56M | $77.68M |
| Total Debt | $350.60M | $346.59M | $338.93M | $334.69M | $328.67M | $320.51M | $318.62M | $314.76M | $284.53M | $- | $195.72M | $129.23M | $122.97M | $73.52M | $20.11M | $3.13M | $3.37M | $3.99M | $3.43M | $4.76M |
| Net Debt | $63.85M | $-112.69M | $137.24M | $-563.24M | $-949.40M | $-642.96M | $-914.60M | $-345.29M | $-501.50M | $-786.03M | $-184.06M | $-248.56M | $-565.97M | $-264.81M | $-468.11M | $-409.16M | $-452.32M | $-445.39M | $-558.96M | $-164.04M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-158.13M | $-518.25M | $-445.72M | $-386.21M | $-307.62M |
| Depreciation and Amortization | $23.36M | $20.45M | $18.39M | $13.92M | $9.93M |
| Deferred Income Tax | $- | $- | $- | $-174.94M | $9.22M |
| Stock Based Compensation | $68.94M | $47.68M | $34.34M | $20.16M | $4.76M |
| Change in Working Capital | $20.04M | $-71.34M | $186.32M | $140.87M | $-23.92M |
| Accounts Receivables | $93.75M | $-98.98M | $50.32M | $24.59M | $-45.00M |
| Inventory | $-17.21M | $-12.71M | $-8.61M | $51.00K | $-643.00K |
| Accounts Payables | $14.06M | $-12.70M | $25.85M | $1.80M | $-4.35M |
| Other Working Capital | $-70.57M | $53.04M | $118.75M | $114.42M | $26.07M |
| Other Non Cash Items | $-98.24M | $128.19M | $6.65M | $187.74M | $84.62M |
| Net Cash Provided by Operating Activities | $-144.03M | $-393.28M | $-200.03M | $-198.47M | $-223.00M |
| Investments in Property Plant and Equipment | $-14.11M | $-20.08M | $-22.27M | $-47.11M | $-49.78M |
| Acquisitions Net | $- | $- | $- | $3.21M | $4.03M |
| Purchases of Investments | $-2.71B | $-4.86B | $-654.97M | $-377.96M | $-72.68M |
| Sales Maturities of Investments | $1.93B | $5.07B | $613.61M | $230.08M | $98.29M |
| Other Investing Activities | $-54.34M | $-91.70M | $-14.71M | $-3.20M | $-4.03M |
| Net Cash Used for Investing Activities | $-850.54M | $92.79M | $-78.34M | $-194.98M | $-24.17M |
| Debt Repayment | $-4.02M | $-3.75M | $-2.60M | $-1.42M | $-2.60M |
| Common Stock Issued | $- | $583.69M | $377.64M | $623.44M | $462.08M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $9.72M | $211.56M | $2.93M | $4.64M | $159.40M |
| Net Cash Used Provided by Financing Activities | $5.70M | $791.49M | $377.98M | $626.66M | $618.88M |
| Effect of Forex Changes on Cash | $-2.08M | $682.00K | $-2.51M | $34.00K | $620.00K |
| Net Change in Cash | $-990.96M | $491.68M | $97.09M | $233.25M | $372.32M |
| Cash at End of Period | $286.75M | $1.28B | $786.03M | $688.94M | $455.69M |
| Cash at Beginning of Period | $1.28B | $786.03M | $688.94M | $455.69M | $83.36M |
| Operating Cash Flow | $-144.03M | $-393.28M | $-200.03M | $-198.47M | $-223.00M |
| Capital Expenditure | $-14.11M | $-22.72M | $-22.27M | $-47.11M | $-49.78M |
| Free Cash Flow | $-158.14M | $-416.00M | $-222.30M | $-245.58M | $-272.78M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $40.51M | $-120.89M | $-18.20M | $-59.79M | $-144.82M | $-62.49M | $-198.84M | $-111.97M | $-135.72M | $-84.80M | $-184.11M | $-41.09M | $-88.33M | $-125.39M | $-91.58M | $-80.90M | $-57.76M | $-67.05M | $-134.88M | $-47.94M |
| Depreciation and Amortization | $6.80M | $5.47M | $5.37M | $5.72M | $5.35M | $5.17M | $8.99M | $5.18M | $5.25M | $5.11M | $4.11M | $3.93M | $3.71M | $3.50M | $3.35M | $3.68M | $1.75M | $2.87M | $3.12M | $2.02M |
| Deferred Income Tax | $- | $- | $- | $- | $-124.37M | $-1.24M | $- | $- | $12.93M | $-60.78M | $77.86M | $- | $-46.91M | $38.01M | $- | $- | $- | $- | $- | $-410.00K |
| Stock Based Compensation | $13.39M | $15.11M | $21.74M | $18.70M | $12.59M | $12.38M | $15.64M | $7.07M | $8.97M | $10.24M | $9.45M | $5.67M | $5.20M | $6.92M | $8.03M | $2.32M | $3.06M | $1.03M | $363.00K | $305.00K |
| Change in Working Capital | $-80.08M | $-17.39M | $9.57M | $94.05M | $-11.57M | $-1.79M | $-19.82M | $-31.84M | $59.27M | $54.96M | $86.73M | $-14.65M | $37.99M | $32.55M | $85.88M | $46.23M | $-49.11M | $6.24M | $7.82M | $-2.92M |
| Accounts Receivables | $-5.58M | $12.36M | $6.51M | $80.47M | $-99.05M | $15.04M | $-14.97M | $34.00K | $-31.00K | $403.00K | $49.99M | $-39.00K | $-48.91M | $13.50M | $60.00M | $75.00M | $-75.00M | $- | $- | $30.00M |
| Inventory | $-6.26M | $-5.08M | $5.03M | $-4.47M | $-5.05M | $-2.82M | $-4.84M | $-2.17M | $75.00K | $-2.27M | $-5.26M | $-1.15M | $-115.00K | $72.00K | $94.00K | $-297.00K | $-287.00K | $155.00K | $-334.00K | $-177.00K |
| Accounts Payables | $7.50M | $-12.72M | $-13.00K | $19.30M | $3.02M | $-4.37M | $26.79M | $-3.08M | $-4.65M | $25.33M | $2.50M | $2.67M | $-4.55M | $592.00K | $- | $4.41M | $- | $- | $- | $537.00K |
| Other Working Capital | $-75.73M | $-11.95M | $-1.95M | $-1.25M | $89.51M | $-9.65M | $-26.79M | $-2.00K | $63.88M | $31.50M | $39.50M | $-16.13M | $91.57M | $18.39M | $25.78M | $-16.84M | $26.17M | $6.09M | $8.15M | $-33.28M |
| Other Non Cash Items | $-62.70M | $41.88M | $-20.14M | $-107.64M | $169.58M | $-12.87M | $113.94M | $-29.08M | $-442.00K | $3.16M | $5.22M | $-32.55M | $18.79M | $-188.00K | $34.05M | $54.11M | $1.80M | $2.68M | $77.99M | $3.14M |
| Net Cash Provided by Operating Activities | $-82.08M | $-75.82M | $-1.65M | $16.18M | $-93.24M | $-60.85M | $-95.73M | $-141.05M | $-49.74M | $-72.11M | $-740.00K | $-78.69M | $-69.55M | $-44.59M | $-57.54M | $-26.79M | $-55.95M | $-64.38M | $-56.88M | $-45.80M |
| Investments in Property Plant and Equipment | $-2.38M | $-2.06M | $-3.42M | $-22.79M | $-25.41M | $-5.47M | $-10.36M | $-4.27M | $-7.52M | $-1.67M | $-559.00K | $-12.53M | $-3.15M | $-12.61M | $-2.42M | $-17.18M | $-12.43M | $-7.09M | $-10.84M | $-15.38M |
| Acquisitions Net | $- | $- | $- | $- | $1 | $-96.00K | $- | $- | $-969.00K | $908.00K | $881.00K | $232.50M | $348.00K | $1.13M | $20.00K | $- | $- | $- | $- | $- |
| Purchases of Investments | $-313.45M | $-54.05M | $-1.47B | $-872.30M | $-1.91B | $-2.52B | $- | $-4.36M | $-125.00M | $-60.00M | $-160.00M | $-309.97M | $-30.40M | $-113.07M | $- | $-50.00M | $- | $- | $- | $-2.12M |
| Sales Maturities of Investments | $233.22M | $400.61M | $797.39M | $498.27M | $2.34B | $2.34B | $- | $50.97M | $163.91M | $190.64M | $170.31M | $90.00M | $130.08M | $20.00M | $- | $50.00M | $- | $- | $- | $- |
| Other Investing Activities | $-5.23M | $-15.41M | $-17.15M | $-16.54M | $907.00K | $-26.18M | $-113.22M | $17.93M | $-5.49M | $-1.99M | $-8.04M | $-232.50M | $-370.00K | $-1.12M | $-168.67M | $-17.15M | $61.16M | $-58.62M | $-9.21M | $-2.12M |
| Net Cash Used for Investing Activities | $-87.84M | $329.08M | $-695.63M | $-396.81M | $405.10M | $-209.07M | $-123.58M | $17.93M | $24.93M | $127.89M | $2.58M | $-232.50M | $96.51M | $-105.67M | $-168.67M | $-17.15M | $61.16M | $-58.62M | $-9.21M | $-17.50M |
| Debt Repayment | $-936.00K | $-1.16M | $-1.16M | $-758.00K | $304.00K | $-1.72M | $- | $-814.00K | $-1.41M | $-703.00K | $-52.00K | $-434.00K | $-422.00K | $-447.00K | $- | $-171.00K | $-803.00K | $- | $- | $-1.62M |
| Common Stock Issued | $- | $- | $2.12M | $1.59M | $621.00K | $2.68M | $- | $- | $624.00K | $377.64M | $- | $- | $323.44M | $1.59M | $302.51M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-75.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $603.00K | $5.41M | $2.12M | $1.59M | $621.00K | $2.68M | $790.05M | $370.00K | $624.00K | $785.00K | $1.06M | $459.00K | $543.00K | $1.59M | $301.75M | $378.00K | $1.46M | $9.66M | $459.80M | $300.75M |
| Net Cash Used Provided by Financing Activities | $-333.00K | $4.25M | $955.00K | $831.00K | $925.00K | $961.00K | $789.89M | $-286.00K | $-783.00K | $377.73M | $1.01M | $25.00K | $323.56M | $1.14M | $301.75M | $207.00K | $661.00K | $9.66M | $459.80M | $148.75M |
| Effect of Forex Changes on Cash | $-2.27M | $524.00K | $9.00K | $-343.00K | $1.45M | $-784.00K | $2.58M | $-2.57M | $-1.11M | $-547.00K | $-864.00K | $10.00K | $78.00K | $-759.00K | $378.00K | $337.00K | $434.00K | $325.00K | $-112.00K | $-27.00K |
| Net Change in Cash | $-172.53M | $258.02M | $-696.32M | $-380.14M | $314.24M | $-269.74M | $573.16M | $-125.98M | $-26.70M | $432.96M | $1.99M | $-311.15M | $350.60M | $-149.88M | $75.92M | $-43.39M | $6.31M | $-113.01M | $393.59M | $85.43M |
| Cash at End of Period | $286.75M | $459.28M | $201.25M | $897.93M | $1.28B | $963.47M | $1.23B | $660.05M | $786.03M | $812.73M | $379.78M | $377.79M | $688.94M | $338.33M | $488.21M | $412.30M | $455.69M | $449.38M | $562.39M | $168.80M |
| Cash at Beginning of Period | $459.28M | $201.25M | $897.57M | $1.28B | $963.83M | $1.23B | $660.05M | $786.03M | $812.73M | $379.78M | $377.79M | $688.94M | $338.33M | $488.21M | $412.30M | $455.69M | $449.38M | $562.39M | $168.80M | $83.36M |
| Operating Cash Flow | $-82.08M | $-75.82M | $-1.65M | $16.18M | $-93.24M | $-60.85M | $-95.73M | $-141.05M | $-49.74M | $-72.11M | $-740.00K | $-78.69M | $-69.55M | $-44.59M | $-57.54M | $-26.79M | $-55.95M | $-64.38M | $-56.88M | $-45.80M |
| Capital Expenditure | $-2.38M | $-2.06M | $-3.42M | $-22.79M | $-25.41M | $-5.47M | $-10.36M | $-4.27M | $-7.52M | $-1.67M | $-559.00K | $-12.53M | $-3.15M | $-12.61M | $-2.42M | $-17.18M | $-12.43M | $-7.09M | $-10.84M | $-15.38M |
| Free Cash Flow | $-84.46M | $-77.89M | $-5.07M | $-6.61M | $-118.65M | $-66.32M | $-106.09M | $-145.33M | $-57.26M | $-73.78M | $-1.30M | $-91.22M | $-72.70M | $-57.20M | $-59.96M | $-43.96M | $-68.38M | $-71.47M | $-67.72M | $-61.18M |
Legend Biotech Dividends
Explore Legend Biotech's dividend history, including dividend yield, payout ratio, and historical payments.
Legend Biotech News
Read the latest news about Legend Biotech, including recent articles, headlines, and updates.
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
With U.S. President Donald Trump's tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertainty.
Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim CFO Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Jon Miller - Evercore Hang Hu - Barclays Yaron Werber - TD Cowen Jessica Fye - JPMorgan Ziyi Chen - Goldman Sachs Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Mitchell Kapoor - H.C. Wainright James Shin - DB Jeet Mukherjee - BTIG Ash Verma - UBS George Farmer - Scotiabank Sean McCutcheon - Raymond James Rick Bienkowski - Cantor Fitzgerald Prem Lachman - Maximus Capital Operator Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call.
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2024, and key corporate highlights.
Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple regulatory approvals and shows significant sales growth, with potential peak sales of at least $3B. The company has an impressive pipeline (with 11 non-CARVYKTI related programs), high growth rates, and strong liquidity stance with $1.2B in cash, ensuring funding into 2026, and low dilution risk.
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT.
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual disease (MRD)-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD, compared to standard therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).1 MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma.1 These results reinforce the clinical value of CARVYKTI® as early as second line and support the recent achievement of overall survival (OS) benefit versus standard therapies1. The MRD negativity findings were featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract #1032) in San Diego, California.1
Legend Biotech: The Story Brightens
Legend Biotech's Carvykti, a CAR-T therapy, has shown significant sales growth since being launched in 2022. The company has some $1.2 billion in cash on its balance sheet and losses are projected to fall dramatically in coming years as revenues soar. Analyst firms are quite optimistic on Legend, with nine analyst firms issuing Buy ratings since Q3 numbers were released with price targets between $73-$94 a share.
Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call Participants Gena Wang - Barclays Kelly Shi - Jefferies Jessica Fye - JPMorgan Kostas Biliouris - BMO Capital James Shin - DB Vikram Purohit - Morgan Stanley Mitchell Kapoor - H.C. Wainright Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Operator Ladies and gentlemen, thank you for standing by.
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stock Picks From Seeking Alpha's September 2024 New Analysts
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies.
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65) in Rio de Janeiro, Brazil.1
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week.
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET.
Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve Gavel - Head of Commercial Development for US and Europe Guowei Fang - CSO Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Kelly Shi - Jefferies Ash Verma - UBS Leonid Timashev - RBC Capital Markets Jonathan Miller - Evercore ISI Yaron Werber - TD Cowen James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright George Farmer - Scotiabank Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for standing by.
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights.
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024.
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results.
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without l.
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend's website. The webca.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LEGN.